secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001193125-26-012259
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation with pipeline progress and 2026 data expectations
--------------------------------------------------------------------------------

- Lead programs VMT-α-NET (SSTR2+ NETs), VMT01 (MC1R melanoma), PSV359 (FAP-α) all in Phase 1/2a trials.
- Proprietary 212Pb-based radioligand platform and chelator designed for broader use; manufacturing underway.
- Phase 1/2 data expected across all three clinical programs in 2026.
- Preliminary anti-tumor activity observed for VMT01 at lower dose; well-tolerated safety profile.
- VMT-α-NET shows compelling anti-tumor activity and best-in-class safety; potential registration study at current dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526012259/0001193125-26-012259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526012259/catx-20260114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-012259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer